Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by PALIT, J.
Right arrow Articles by NUKI, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by PALIT, J.
Right arrow Articles by NUKI, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 British Society for Rheumatology

other

A MULTICENTRE DOUBLE-BLIND COMPARISON OF AURANOFIN, INTRAMUSCULAR GOLD THIOMALATE AND PLACEBO IN PATIENTS WITH PSORIATIC ARTHRITIS

J. PALIT1, J. HILL3, H. A. CAPELL2,1, J. CAREY2, S. O'N. DAUNT4, M. I. D. CAWLEY4, H. A. BIRD3 and G. NUKI1

1Rheumatic Diseases Unit, Northern General Hospital Edinburgh EH5 2DQ
2Centre for Rheumatic Diseases, Royal Infirmary Glasgow G4 OSF
3Clinical Pharmacology Unit, Royal Bath Hospital Harrogate HG1 2PS
4Rheumatology Unit, Southampton General Hospital Southampton SO9 4XY

Correspondence to: 1Correspondence to Dr H. Capell, Centre for Rheumatic Diseases, Glasgow Royal Infirmary, 84 Castle Street, Glasgow G4 0SF.

The efficacy and safety of the oral gold compound auranofin and intramuscular gold thiomalate have been compared in a placebo-controlled, double-blind, four-centre trial in 82 patients with psoriatic arthritis requiring remittive drug therapy. There were statistically significant falls in Ritchie articular index, visual analogue pain score and ESR at 12 and 24 weeks following i.m. gold but no significant changes in the auranofin group. Intramuscular gold was safe and more effective than auranofin as a second-line, suppressive antirheumatic agent for patients with psoriatic arthritis when followed for 6 months.

KEY WORDS: Second-line treatment, Oral gold, Toxicity, Effectiveness


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
V Ravindran, D L Scott, and E H Choy
A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis
Ann Rheum Dis, June 1, 2008; 67(6): 855 - 859.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
P Nash and D O Clegg
Psoriatic arthritis therapy: NSAIDs and traditional DMARDs
Ann Rheum Dis, March 1, 2005; 64(suppl_2): ii74 - ii77.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
N. Pipitone, G. H. Kingsley, A. Manzo, D. L. Scott, and C. Pitzalis
Current concepts and new developments in the treatment of psoriatic arthritis
Rheumatology, October 1, 2003; 42(10): 1138 - 1148.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
P J Mease
Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors
Ann Rheum Dis, April 1, 2002; 61(4): 298 - 304.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
P J Mease
Cytokine blockers in psoriatic arthritis
Ann Rheum Dis, November 1, 2001; 60(90003): iii37 - 40.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.